Refine by
Vaccine Trials Articles & Analysis
54 news found
The low cost and scalability of Lumen’s production platform, coupled with easy, needle-free administration, could greatly expand real-world access to malaria vaccines. “We are excited to be working with Lumen on this potentially groundbreaking application of their unique technology platform,” said senior author Sean Murphy, M.D., Ph.D., Associate Professor at ...
An article presenting analyses of Continuous Glucose Monitoring (CGM) data from the randomised, placebo-controlled Phase 2b trial DIAGNODE-2 that assessed three intralymphatic injections of the therapeutic diabetes vaccine Diamyd®, has been published in the peer-reviewed scientific journal The Journal of Clinical Endocrinology & Metabolism (JCEM). ...
The prediction algorithm will be evaluated in clinical prevention trials where individuals at high risk for type 1 diabetes will be treated preventively with the diabetes vaccine Diamyd®. ...
The last patient in the investigator-initiated clinical trial DIAGNODE-B has received its additional injection (“booster”) of the therapeutic diabetes vaccine Diamyd®. ...
Updated 12-month results from the open-label investigator-initated Phase II clinical trial GADinLADA that assessed three intralymphatic injections of the therapeutic diabetes vaccine Diamyd® in individuals diagnosed with Latent Autoimmune Diabetes in Adults (LADA) were presented today at the European Association for the Study of Diabetes (EASD) conference in ...
An article presenting the 5-month interim results from the open-label trial GADinLADA that assessed three intralymphatic injections of the therapeutic diabetes vaccine Diamyd®, has been published in the peer-reviewed scientific journal Frontiers in Endocrinology. ...
Clínica Universidad de Navarra has completed a randomised controlled study of Ondine Biomedical’s nasal photodisinfection technology in fully vaccinated COVID-19 patients with early symptoms of COVID-19. “Top-line results from this clinical trial suggest that nasal photodisinfection treatment rapidly and substantially suppresses SARS-CoV-2 ...
The primary endpoints of safety and tolerability were met in the open-label investigator-initiated Phase II clinical trial GADinLADA, in which the diabetes vaccine Diamyd® was administered directly into the lymph node of 14 patients aged 30 to 70 years with the autoimmune form of diabetes called LADA (Latent Autoimmune Diabetes in Adults). ...
By creating a unique assembly of data from previous prevention and intervention trials in Type 1 diabetes, including trials conducted with the therapeutic diabetes vaccine Diamyd®, T1DC aims to optimize the planning and conduct of clinical trials by developing novel solutions including clinical trial ...
Utilizing its custom HQ plasmid offering which, being manufactured to the principles of GMP, serves as a phase-appropriate solution for early clinical trials, Ziphius Vaccines will benefit from accelerated timelines without compromising on quality. ...
FDA Orphan Drug Designation reflects urgent need for new therapies for glioblastoma (GBM) patients Next steps for development of VBI-1901 : Q3 2022: Expected initiation of randomized, controlled clinical study in recurrent GBM patients with potential to support accelerated approval application Q4 2022: Expected initiation of randomized, controlled evaluation in primary GBM patients as part ...
The double-blinded trial is testing Calviri’s vaccine aimed at broadly preventing cancers in dogs. ...
ByCalviri
Median overall survival and 18-month overall survival data continue to show improvements over historical controls1 One patient remains on protocol progression-free beyond two years, with a sustained 93% tumor reduction relative to baseline Next steps : Recurrent GBM: randomized, controlled evaluation with potential to support accelerated approval application expected to initiate in Q3 2022 ...
Researchers running the University of Oxford-led Com-COV programme have launched a further national study assessing different options for a (third dose) booster vaccination for young people aged 12 to 15. Backed through funding from the Vaccines Taskforce and National Institute for Health Research (NIHR), the Com-COV 3 trial will seek to recruit ...
The patients will receive the booster injections within the next month. About DIAGNODE-3 The Phase III trial DIAGNODE-3, with the therapeutic vaccin Diamyd®, willl enroll approximately 330 individuals aged 12 to 28, recently diagnosed with type 1 diabetes, who carry the HLA DR3-DQ2 haplotype. ...
(Nasdaq: VAXX), a US company pioneering the development of a new class of immunotherapeutic vaccines, today announced that they will co-fund the ongoing global pivotal Phase 3 clinical trial of Vaxxinity’s next generation UB-612 COVID-19 vaccine candidate as a heterologous – or ‘mix-and-match’ – booster dose. ...
ByVaxxinit
INOVIO is evaluating candidate VGX-3100 in two Phase 3 trials for precancerous high-grade cervical dysplasia caused by HPV-16 and/or HPV-18. INOVIO is also evaluating INO-4800, a DNA vaccine candidate against COVID-19, in a global Phase 3 trial. Partners and collaborators include Advaccine, ApolloBio Corporation, AstraZeneca, The Bill & ...
We have also completed enrollment in a Phase 1b trial for Lassa fever, a Phase 1b trial for an Ebola vaccine booster, as well as the first part of our Phase 2 trial for Middle East Respiratory Syndrome (MERS), showcasing the depth and breadth of our DNA medicines pipeline to support global public health efforts against potential ...
INOVIO is evaluating candidate VGX-3100 in two Phase 3 trials for precancerous high-grade cervical dysplasia caused by HPV-16 and/or HPV-18. INOVIO is also evaluating INO-4800, a DNA vaccine candidate against COVID-19, in a global Phase 3 trial. Partners and collaborators include Advaccine, ApolloBio Corporation, AstraZeneca, The Bill & ...
Upcoming Milestones: Topline data from Phase 1 expected H1 2022 Initiation of Phase 2/3 oral COVID-19 vaccine trials expected H2 2022 Phase 2 NASH Trial: 50% Enrollment Completed Over 50% of patients have been enrolled in the U.S. and Israel in our double-blind Phase 2 trial of ORMD-0801 for the treatment of ...